Table 3 *Empiric, first adequate and definitive antimicrobial choice and associated 30-day case-fatality
Empiric antibiotic choice | Case fatality rate | First adequate antibiotic choice | Case fatality rate | Definitive antimicrobial therapy | Case fatality rate |
|---|---|---|---|---|---|
Antibiotics with activity against AmpC- producing Enterobacteriaceae | |||||
Aminoglycoside | 7/52 (13%) | Aminoglycoside | 10/80 (13%) | Aminoglycoside | 15/132 11%) |
Beta-lactam/Beta-lactamase inhibitor combination | 15/131 (11%) | Beta-lactam/Beta-lactamase inhibitor combination | 16/137 (12%) | Beta-lactam/Beta-lactamase inhibitor combination | 10/22 (45%) |
Carbapenem | 0/16 (0%) | Carbapenem | 3/31 (9.7%) | Carbapenem | 5/45 (11%) |
Cefepime | 1/3 (33%) | Cefepime | 1/5 (20%) | Cefepime | 1/4 (25%) |
Cefoxitin | 0/1 (0%) | Cefixime | 0/10 (0%) | Cefotaxime | 0/2 (0%) |
Ceftazidime | 1/15 (6.7%) | Ceftazidime | 0/10 (0%) | Ceftazidime | 0/1 (0%) |
Ceftriaxone | 11/85 (13%) | Ceftriaxone | 12/97 (12%) | Ceftriaxone | 1/7 (14%) |
Cefuroxime | 1/5 (20%) | Colistin | 0/1 (0%) | Colistin | 0/1 (0%) |
Colistin | 0/1 (0%) | Fluoroquinolone | 16/106 (15%) | Fluoroquinolone | 30/231 (13%) |
Fluoroquinolone | 10/76 (13%) | TMP/SMX | 0/9 (0%) | TMP/SMX | 0/14 (0%) |
TMP/SMX | 2/14 (14%) | ||||
Antibiotics unlikely to have activity against AmpC- producing Enterobacteriaceae | |||||
Ampicillin | 3/30 (10%) | ||||
Azithromycin | 1/5 (20%) | ||||
Cefazolin | 5/39 (13%) | ||||
Cephalexin | 0/2 (0%) | ||||
Clindamycin | 0/4 (0%) | ||||
Cloxacillin | 2/7 (29%) | ||||
Linezolid | 0/1 (0%) | ||||
Metronidazole | 12/68 (18%) | ||||
Penicillin | 0/3 (0%) | ||||
Rifampin | 0/3 (0%) | ||||
Vancomycin | 6/37 (16%) |